Introduction {#sec1}
============

*Neisseria gonorrhoeae* is the etiological agent of gonorrhoea, one of the most common bacterial sexually transmitted infections. In 2012, the World Health Organization (WHO) estimated about 78 million of new global urogenital cases among adults per year \[[@cit0001]\]. Laboratory diagnostics of gonorrhoea includes microscopy, nucleic acid amplification tests (NAATs), and *in vitro* culture. Culture is the only method that allows for antimicrobial susceptibility testing and accordingly the culture remains essential \[[@cit0002]\]. Initially, *N. gonorrhoeae* showed a high susceptibility to many classes of antimicrobials and the treatment of gonorrhoea did not pose any major problems. However, since the first antimicrobials (sulfonamides) were introduced for treatment of gonorrhoea in the mid-1930s, *N. gonorrhoeae* has shown an extraordinary capacity to develop or acquire resistance to all therapeutic antimicrobials recommended. At present, internationally there is a high prevalence of *N. gonorrhoeae* strains with resistance to majority of antimicrobials earlier and currently widely used for treatment (e.g., sulfonamides, penicillins, earlier generation cephalosporins, tetracyclines, earlier generation macrolides and fluoroquinolones) \[[@cit0003]\]. In the mid-1990s, the first strains resistant to ceftriaxone and cefixime, the last remaining options for empiric first-line monotherapy of gonorrhoea, emerged in Japan \[[@cit0004]\], and subsequently started to spread internationally. In the recent decade, decreased susceptibility or resistance to ceftriaxone and cefixime has been reported in most countries worldwide \[[@cit0005]\]. This development is a major public health concern and in 2017, *N. gonorrhoeae* was included on the WHO list of 12 antibiotic-resistant pathogens that pose a global threat to human health and require priority efforts towards developing new antibiotics \[[@cit0006]\].

Antimicrobial resistance of *N. gonorrhoeae* isolates in Poland {#sec2}
===============================================================

In Poland, no gonococcal isolates with resistance to ceftriaxone have been identified \[[@cit0007]--[@cit0010]\]. However, the proportion of isolates with decreased susceptibility to these antibiotic has increased, including the rate of isolates with a ceftriaxone minimum inhibitory concentration (MIC) of 0.125 mg/l (exactly at the resistance breakpoint) \[[@cit0008], [@cit0009]\]. In 2016 resistance to cefixime was detected first time (5.3% of isolates from Poland in Euro-GASP). The prevalence of azithromycin-resistant isolates in 2010--2015 ranged from 5.4% to 19.0% \[[@cit0007], [@cit0008], [@cit0010], [@cit0011]\]. Some azithromycin-resistant strains belonging to the *Neisseria gonorrhoeae* multiantigen sequence typing (NG-MAST) genogroups G1407, G1478, and G21 exhibited a C2611T mutation in all the four 23S rRNA alleles, which result in an azithromycin MIC of 4--32 mg/l \[[@cit0012]\]. The prevalence of ciprofloxacin-resistant isolates in 2010--2015 varied from 50.0% to 71.7% \[[@cit0007], [@cit0008], [@cit0010], [@cit0013]\]. Most isolates were resistant or intermediately resistant, with only 2.8% and 1.7% of strains susceptible, to benzyl penicillin, in 2012 and 2013, respectively \[[@cit0008], [@cit0009]\]. The prevalence of penicillinase-producing *N. gonorrhoeae* (PPNG) strains has been mainly low \[[@cit0008], [@cit0009], [@cit0014]\] illustrating that most of the resistance to benzyl penicillin is chromosomally-mediated. The prevalence of tetracycline-resistant isolates in 2010--2013 ranged from 38.0% to 50.8% \[[@cit0008], [@cit0015]\].

Antimicrobial resistance of *N. gonorrhoeae* isolates all over the world {#sec3}
========================================================================

In the recent decade, *N. gonorrhoeae* isolates with decreased susceptibility or resistance to ceftriaxone and cefixime have been identified in most countries globally \[[@cit0005]\]. The first gonococcal strain with high-level resistance to ceftriaxone (MIC = 2 mg/l) and cefixime (MIC = 4 mg/l) was isolated in Kyoto, Japan, in 2009 \[[@cit0016], [@cit0017]\]. Another strain with high-level resistance to ceftriaxone and cefixime (MICs of 1 mg/l and 2 mg/l, respectively) was isolated in France in 2010 \[[@cit0018]\], and two isolates similar to the French strain were later identified in Spain in 2012 \[[@cit0019]\]. None of these strains appear to have spread further \[[@cit0005], [@cit0010], [@cit0020]--[@cit0026]\], which is likely due to a suboptimal biological fitness of these strains \[[@cit0027]\]. Subsequently, additional sporadic ceftriaxone-resistant isolates with a ceftriaxone MIC of ≥ 0.5 mg/l have also been characterized in more detail during the latest years, for example, isolates from Australia in 2013 and 2017 \[[@cit0028], [@cit0029]\], Argentina in 2014 \[[@cit0030]\], Japan in 2014 and 2015 \[[@cit0031], [@cit0032]\], Denmark in 2017 \[[@cit0033]\], and Canada in 2017 \[[@cit0034]\]. Retrospective studies in China \[[@cit0035]--[@cit0037]\] and Japan \[[@cit0038]\] have also identified relatively high proportions of ceftriaxone-resistant isolates. It is a grave public health concern that the first three *N. gonorrhoeae* isolates globally with resistance to ceftriaxone combined with high-level resistance to azithromycin (MIC ≥ 256 mg/l) were identified at the beginning of 2018 in the United Kingdom (1 case) \[[@cit0039]\] and a few months later in Australia (2 cases) \[[@cit0040]\]. These gonococcal strains pose a main threat to the first-line dual antimicrobial therapy (ceftriaxone of 250--500 mg administered intramuscularly plus azithromycin of 1--2 γ administered orally) recommended in Europe \[[@cit0041]\] and other settings worldwide.

In the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), 26 (0.26% of 9910 isolates) ceftriaxone-resistant isolates were reported from 2011 to 2015 (10 in 2011), 3 in 2012, 7 in 2013, 5 in 2014 and 1 isolate in 2015). These ceftriaxone-resistant isolates were cultured in Greece (*n* = 4), Spain (*n* = 6), Germany (*n* = 10) and Austria (*n* = 3), and one isolate each in Norway, Ireland, and Slovenia \[[@cit0010], [@cit0021]--[@cit0025]\]. Resistance rates to cefixime have been substantially higher and, in 2012--2014, cefixime-resistant isolates were found in most European countries; in 2013, their prevalence was highest in Spain (15.1%) and Greece (14.5%), and in 2014, in Belgium (12.1%). Resistance to azithromycin has also been found in nearly all European countries (except for Estonia and Iceland), with the highest prevalence in Greece (39.6%) and Ireland (37.6%) in 2014, and in Greece (22.7%) in 2013. Resistance to ciprofloxacin was found in all European countries, with the highest rates (more than 70%) in Austria, Greece, and Germany, and the lowest in Estonia (2.0%); PPNG strains were most common in Austria, Sweden, and Norway \[[@cit0010], [@cit0021]--[@cit0024]\].

The prevalence of resistance to cefixime, azithromycin, ciprofloxacin in various countries stratified by years is presented in [Table 1](#t0001){ref-type="table"}. For countries continuously participating in Euro-GASP, the presented resistance data span 2012--2015 \[[@cit0010], [@cit0021]--[@cit0025]\]. Moreover, resistance data from some non-EU/EEA WHO European region countries (Belarus and Russia) have been included \[[@cit0042]--[@cit0045]\].

###### 

Antimicrobial resistance of *Neisseria gonorrhoeae* in the European Union (EU)/European Economic Area (EEA) and some non-EU/EEA WHO European region countries (Belarus and Russia)

  Country                                        Year                \% of resistance   PPNG (%)                          
  ---------------------------------------------- ------------------- ------------------ --------------- ----------------- -------------
  Austria[\*](#tf1-1){ref-type="table-fn"}       2012/13/14/15       5/6/0/0            3/6/2/3         74/72/53/66       32/26/24/32
  Belarus                                        2012/13             0/3                Jan-00          21/28             0/0
  Belgium[\*](#tf1-1){ref-type="table-fn"}       2012/13/14/15       1/6/12/11          2/2/4/3         56/56/58/50       10/16/19/14
  Croatia[\*](#tf1-1){ref-type="table-fn"}       2015                0                  0               38                13
  Cyprus[\*](#tf1-1){ref-type="table-fn"}        2015                0                  0               67                0
  Denmark[\*](#tf1-1){ref-type="table-fn"}       2012/13/14/15       12/12/6/0          14/9/4/3        59/58/33/31       18/8/9/9
  Estonia[\*](#tf1-1){ref-type="table-fn"}       2014/15             0/0                0/0             28-Feb            0/0
  France[\*](#tf1-1){ref-type="table-fn"}        2012/13/14/15       2/4/1/0            0/0/11/6        39/45/51/42       7/33/ND/ND
  Germany[\*](#tf1-1){ref-type="table-fn"}       2012/13/14/15       6/13/0/2           2/4/3/2         74/63/63/62       19/17/13/16
  Greece[\*](#tf1-1){ref-type="table-fn"}        2012/13/14/15       6/15/5/11          6/23/40/22      69/72/70/77       12/3/6/11
  Hungary[\*](#tf1-1){ref-type="table-fn"}       2012/13/14/15       6/7/1/2            0/2/1/5         66/68/55/53       1/7/14/14
  Iceland[\*](#tf1-1){ref-type="table-fn"}       2013/14/15          0/0/0              0/0/0           40/58/29          ND/22/0
  Ireland[\*](#tf1-1){ref-type="table-fn"}       2012/13/14/15       4/0/0/1            9/3/38/18       23/26/35/46       3/5/2/11
  Italy[\*](#tf1-1){ref-type="table-fn"}         2012/13/14/15       6/0/2/0            2/1/6/2         65/63/78/71       9/9/8/7
  Latvia[\*](#tf1-1){ref-type="table-fn"}        2012/13/14/15       3/3/0/0            5/16/14/0       39/26/19/11       0/13/0/0
  Malta[\*](#tf1-1){ref-type="table-fn"}         2012/13/14/15       0/0/0/0            0/0/5/14        56/36/57/66       19/6/10/24
  Netherlands[\*](#tf1-1){ref-type="table-fn"}   2012/13/14/15       0/0/2/1            1/1/2/4         34/35/32/37       ND/ND/ND/ND
  Norway[\*](#tf1-1){ref-type="table-fn"}        2012/13/14/15       6/5/6/1            13/11/5/4       56/80/74/59       27/29/29/25
  **Poland**[\*](#tf1-1){ref-type="table-fn"}    **2012/13/14/15**   **0/ND/0/0**       **10/19/9/5**   **69/62/65/57**   **4/9/0/5**
  Portugal[\*](#tf1-1){ref-type="table-fn"}      2012/13/14/15       0/0/0/0            2/18/17/17      41/47/36/37       8/6/7/8
  Russia                                         2012/2015           ND/ND              17/2            26/40             0/0
  Slovakia[\*](#tf1-1){ref-type="table-fn"}      2012/13/14/15       4/5/1/4            3/2/4/2         54/47/68/54       6/4/25/26
  Slovenia[\*](#tf1-1){ref-type="table-fn"}      2012/13/14/15       4/1/1/0            15/0/2/0        40/63/45/35       9/14/22/5
  Spain[\*](#tf1-1){ref-type="table-fn"}         2012/13/14/15       15/15/0/2          10/8/7/3        58/66/68/65       15/13/19/20
  Sweden[\*](#tf1-1){ref-type="table-fn"}        2012/13/14/15       0/0/0/0            6/9/4/14        57/60/57/45       31/18/19/13
  UK[\*](#tf1-1){ref-type="table-fn"}            2012/13/14/15       0/1/0/0            2/0/1/13        28/32/33/40       5/10/9/19
  EU/EEA\*\*                                     2012/13/14/15       4/5/2/2            5/5/8/7         50/53/51/49       13/13/14/15

Countries participating in Euro-GASP included in the EU/EEA average, CFX -- cefixime (MIC \> 0.125 mg/l), AZT -- azithromycin (MIC \> 0.5 mg/l), CIP -- ciprofloxacin (2012: MIC \> 0.5 mg/l; 2013--2015: MIC \> 0.064 mg/l), PPNG -- penicillinase-producing Neisseria gonorrhoeae, ND -- not done.

Molecular epidemiological typing of *N. gonorrhoeae* {#sec4}
====================================================

Molecular epidemiological typing, particularly linked to antimicrobial resistance and epidemiological data of patients, can be exceedingly valuable. The typing can identify the spread of antimicrobial resistant strains, potentially more virulent strains, and describe changing strain distributions overall and among risk groups \[[@cit0046], [@cit0047]\].

For *N. gonorrhoeae*, NG-MAST has been the most frequently used molecular typing method \[[@cit0008], [@cit0012], [@cit0046]--[@cit0048]\]. NG-MAST includes sequencing of parts of two more variable genes: *porB* (encoding the transmembrane channel proteinporin B (PorB)) and *tbpB* (encoding the transferrin-binding protein B (TbpB)). The sequences are subsequently assigned allele numbers and, at present, more than 9800 *porB* alleles and 2,700 *tbpB* alleles have been described. The combination of the *porB* and *tbpB* allele number is assigned an NG-MAST sequence type (ST). At present, approximately 16,800 NG-MAST STs have been described ([www.ng-mast.net](http://www.ng-mast.net)).

The proportions of different NG-MAST STs in different countries have been summarized in [Table 2](#t0002){ref-type="table"} \[[@cit0008], [@cit0035], [@cit0036], [@cit0042]--[@cit0044], [@cit0049]--[@cit0057]\]. Briefly, in 2009--2010, the most common STs in Europe were as follows: ST1407 (15.6%) of genogroup G1407; ST2992 (7.1%) of G2992; and ST225 (4.7%) of G225. ST1407 predominated in the European countries -- Austria, Belgium, Italy, the Netherlands, Portugal, Romania, Slovenia, Spain, Switzerland, the United Kingdom \[[@cit0058]\], but also in Canada \[[@cit0050], [@cit0051]\] and the USA \[[@cit0056], [@cit0059]\]. ST2992 predominated in Ireland and Norway, while ST225 predominated in Denmark, Sweden, and on Malta \[[@cit0058]\]. In 2013, the most frequent STs in Europe remained ST1407 (7.6%) and ST2992 (6.7%), with an increase in the rates of ST2400 (3.9%, genogroup G2400). ST1407 predominated in Belgium, Hungary, Norway, Portugal, Slovenia, Spain and Switzerland. ST2992 predominated in Ireland, Italy, on Malta, in the Netherlands, and the United Kingdom. ST2400 was detected in eight countries but was not the predominant ST in any of them \[[@cit0055]\].

###### 

Prevalence of NG-MAST sequence types in Europe and selected non-European countries

  -------------------------------------------------------------------------------------
  Country          Year          Sequence type (ST)              \% ST
  ---------------- ------------- ------------------------------- ----------------------
  Australia        2011--2013    758/9716/7126                   22/13/11

  Austria          2010\         1407/387/359/5600\              32/10/8/8\
                   2013          3785/11575/4995/387/225         17/11/7/7/7

  Belarus          2010--2013    1993/807/285/9735               28/7/4/4

  Belgium          2010\         1407/387/2992\                  14/12/8\
                   2013          1407/387/2992                   16/15/15

  Canada           2010\         1407/3150/3158\                 13/12/9\
                   2011\         1407/3307/3550\                 15/10/6\
                   2012\         1407/2400/3150\                 11/7/7\
                   2013\         2400/9663/5985\                 12/7/6\
                   2014          2400/5985/10451                 14/14/10

  China            2012--2013    2318/1866/4846                  3/2/1

  Denmark          2010\         225/3158/1407\                  12/12/6\
                   2013          1993/1407/2400                  18/13/7

  France           2010\         2/2992/1407\                    14/14/8\
                   2013          645/11352/225/2400/2992/\       9/5/4/4/4/\
                                 3149/ 4995/5624/11357           4/4/4/4

  Germany          2010\         25/1407/5425\                   32/28/6\
                   2013          4995/25/359/5441/9500           8/6/6/6/6

  Greece           2010\         5405/5505/1407\                 16/16/12\
                   2013          3128/225/4730/11055             19/10/10/10

  Greenland        2012--2013    210/9816/2400                   50/26/10

  Hungary          2010\         5332/356/1407/5333\             29/12/12/12\
                   2013          1407/995/387/8115/11046         21/13/6/6/6

  Ireland          2010\         2992/384/1407\                  32/12/6\
                   2013          2992/384/21/437/10843/649/\     16/11/4/4/ 4/4/4/4/4
                                 2400/4643/10846                 

  Italy            2010\         1407/2992/995\                  34/10/10\
                   2013          2992/6360/2400/1407             18/12/12/10

  Latvia           2009--2010\   3227/5185/5340/225\             41/10/7/7\
                   2013          5/10828/21/4269                 37/13/8/8

  Malta            2009--2010\   225/5463/1407/4949\             46/12/6/6\
                   2013          2992/484/10788/                 33/14/14

  Netherlands      2010\         1407/2992/5402/2400\            16/7/7/6\
                   2013          2992/2400/8919                  10/10/6

  Norway           2009--2010\   2992/1407/4347\                 23/14/10\
                   2013          1407/4275/2400                  9/7/6

  Pakistan         2012--2014    338/3328/10876/10886            3/3/3/3

  **Poland**       **2010**\     **1405/5421/225**\              **18/18/14**\
                   **2011**\     **1407/2992/8379**\             **13/13/9**\
                   **2012**      **1407/8391/1861/2992**         **43/7/5/5**

  Portugal         2009--2010\   1407/1034/2992\                 14/8/8\
                   2013          1407/7445/2                     16/11/5

  Romania          2010          1407/4120/3952/5330             22/22/11/11

  Russia           2011--2012\   807/5714/228\                   8/6/3\
                   2015          9476/807/1544/5714/12531        11/8/5/5/5

  Slovakia         2010\         437/5595/5598\                  26/20/10\
                   2013          1407/359/11042                  14/14/13

  Slovenia         2009--2010\   1407/225/5570\                  28/16/10\
                   2013          21/10801/10800/10798            13/13/9/9

  Spain            2009--2010\   1407/2992/292/3149/1861\        28/9/4/4/4\
                   2013          1407/7232/2992/21               11/8/7/7

  Sweden           2010\         225/2992/5175/5177/5188/5210\   8/6/6/6/6/6\
                   2013          5445/7445/7164                  10/6/6

  Switzerland      2009\         1407/2058\                      38/25\
                   2011          1407/2992                       22/22

  United Kingdom   2010\         1407/2/51\                      14/6/6\
                   2013          2992/51/4995                    10/10/9

  USA              2011          1407/7268/5895                  4/2/1
  -------------------------------------------------------------------------------------

NG-MAST -- Neisseria gonorrhoeae multiantigen sequence typing.

In recent years, whole genome sequencing (WGS) has been increasingly used for epidemiological typing of *N. gonorrhoeae*. Compared to NG-MAST, WGS has a substantially higher and more accurate resolution and can identify multidrug-resistant clades linked to risk groups and additionally predict antimicrobial resistance with a relatively high sensitivity and specificity \[[@cit0012], [@cit0052], [@cit0059], [@cit0060]\]. The WGS will likely be the method of choice for molecular epidemiology and in antimicrobial resistance surveillance of *N. gonorrhoeae* soon. However, appropriate funding, capacity building and quality assurance remain essential for this transition.

Molecular epidemiological typing of *N. gonorrhoeae* isolated in Poland {#sec5}
=======================================================================

In Poland, *N. gonorrhoeae* isolates cultured in 2010-2012 have been examined by NG-MAST \[[@cit0008]\]. The most common STs in 2010 were ST5421 (17.9%; G1479), ST1405 (17.9%; G1405), and ST225 (14.3%; G225). In 2011, the most prevalent STs were the multidrug-resistant ST1407 (13.0%; G1407), ST2992 (13.0%; G2992), and ST8379 (8.7%; G8379). In 2012, nearly half of the isolates were assigned as ST1407 (44.3%; G1407), followed by ST8391 (6.5%; G5043), ST2992 (4.6%; G2992), ST1861 (4.6%; G1861), ST21 (3.7%; G21), and ST8392 (3.7%; G8392) \[[@cit0008]\].

Conclusions {#sec6}
===========

The extensive spread of the multidrug-resistant *N. gonorrhoeae* NG-MAST G1407 in Europe, including Poland, has been raising major concerns. However, fortunately the prevalence of G1407 significantly decreased from 2009/2010 to 2013 in Europe \[[@cit0060]\] and no isolates resistant to ceftriaxone have been detected in Poland so far. Nevertheless, isolates with ceftriaxone MIC exactly at the ceftriaxone resistance breakpoint (MIC = 0.125 mg/l) have been identified in Poland and ceftriaxone-resistant isolates have been cultured in neighboring countries. In 2016 the first cefixime-resistant isolates were observed in Poland. Furthermore, sporadic ceftriaxone-resistant isolates belonging to other NG-MAST genogroups and with a ceftriaxone MIC of ≥ 0.5 mg/l have also been identified and characterized in more detail during the latest years, e.g. isolates from Australia \[[@cit0028], [@cit0029]\], Argentina \[[@cit0030]\], Japan \[[@cit0031], [@cit0032]\], Denmark \[[@cit0033]\] and Canada \[[@cit0034]\]. Recently the first three *N. gonorrhoeae* isolates in the world with resistance to ceftriaxone combined with high-level resistance to azithromycin (MIC ≥ 256 mg/l) have been identified. Consequently, it is a major concern that *N. gonorrhoeae* strains with resistance to ceftriaxone will be introduced and spreading in Poland in the near future. An enhanced, quality assured surveillance of antimicrobial resistance and antimicrobial resistance determinants in *N. gonorrhoeae* is essential in Poland, as well as in most other countries.
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